Chondrosarcoma

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
3 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Kinase inhibitor 1 substance
Phase III: 1 Phase II: 1 Phase I (Other): 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • Institut De Recherches Internationales Servier IRIS Commercial
    IVOSIDENIB
    2023-508507-20-00 7 countries 2025 n=50
    Recruiting

Phase II

1 trial
  • Inhibrx Biosciences Inc. Commercial
    OZEKIBART
    2024-517528-20-00 6 countries 2022 n=97 Orphan
    Ended

Phase I (Other)

1 trial
  • Hutchmed Ltd. Commercial
    IMP not specified
    2024-516370-30-00 1 country 2021 n=24
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Hutchmed Ltd. Commercial 1 Phase I (Other) 0
Inhibrx Biosciences Inc. Commercial 1 Phase II 0
Institut De Recherches Internationales Servier IRIS Commercial 1 Phase III 1
New trials by year
2021
1
2022
1
2025
1
← All indication landscapes